Form 4 Filing for LIGAND PHARMACEUTICALS INC

Stephen L. Sabba, a director at LIGAND PHARMACEUTICALS INC, reported transactions on June 16, 2026. He acquired 2,145 shares of Common Stock at a price of $66.13 per share, bringing his post-transaction total to 35,774 shares. Concurrently, he disposed of 2,145 shares of Common Stock at a price of $254.00 per share, resulting in a post-transaction total of 33,629 shares. Additionally, Mr. Sabba was granted a non-qualified stock option to buy 2,145 shares of Common Stock, with an exercise price of $66.13. This grant was adjusted due to the separation of OmniAb Inc. from the company. The filing also notes that 836 restricted shares were previously reported.